<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04508660</url>
  </required_header>
  <id_info>
    <org_study_id>CGB-400-001b</org_study_id>
    <nct_id>NCT04508660</nct_id>
  </id_info>
  <brief_title>CGB-400 for the Reduction of Facial Redness</brief_title>
  <official_title>Effectiveness of CGB-400 (Cosmetic) for the Reduction of Facial Redness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CAGE Bio Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ethica Clinical Research Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CAGE Bio Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label multicenter study using CGB-400 Gel (cosmetic) to reduce facial redness&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Open-label multicenter study to evaluate the ability of CGB-400 Gel to reduce&#xD;
      facial redness typically associated with rosacea. Approximately 25 subjects will be enrolled.&#xD;
&#xD;
      Subjects will receive study treatment for 4 weeks and attend a total of 4 study visits (BL,&#xD;
      W1, W2, W4).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 26, 2018</start_date>
  <completion_date type="Actual">April 18, 2019</completion_date>
  <primary_completion_date type="Actual">April 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator's Global Assessment of Redness (IGA-R)</measure>
    <time_frame>4 weeks</time_frame>
    <description>5-point scale (0: no redness; 1: slight redness; 2: Definite redness; 3: Marked redness and 4: Fiery redness)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Assessment of Redness (IGA-R)</measure>
    <time_frame>Day 0, Week 1, Week 2</time_frame>
    <description>5-point scale (0: no redness; 1: slight redness; 2: Definite redness; 3: Marked redness and 4: Fiery redness)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment</measure>
    <time_frame>Week 1, Week 2, Week 4</time_frame>
    <description>5-point scale (0: excellent effectiveness; 1: good effectiveness; 2: Effective; 3: No significant benefit and 4: No benefit at all)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bumps/Blemishes Count</measure>
    <time_frame>Day 0, Week 1, Week 2, Week 4</time_frame>
    <description>Numerical count of Bumps/Blemishes</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Subjects with facial redness</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application twice daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CGB-400</intervention_name>
    <description>BID application</description>
    <arm_group_label>Subjects with facial redness</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Outpatient, male or female of any race, 18 years of age or older. Female subjects of&#xD;
             childbearing potential must have a negative UPT at Baseline and practice a reliable&#xD;
             method of contraception throughout the study.&#xD;
&#xD;
          2. Facial redness associated with rosacea.&#xD;
&#xD;
          3. Facial redness (IGA-R) score of 2 or 3 (i.e., mild or moderate).&#xD;
&#xD;
          4. Absence of any skin conditions that could interfere with the visual erythema&#xD;
             assessments.&#xD;
&#xD;
          5. Willing to forego any other topical or non-topical treatment on the study areas during&#xD;
             treatment (other than sun protection or the study specified face wash and&#xD;
             moisturizer).&#xD;
&#xD;
          6. Willing to use the provided skincare regimen (e.g., face wash and moisturizer) over&#xD;
             the duration of the study.&#xD;
&#xD;
          7. Sign the IRB-approved ICF (which includes HIPAA) prior to any study-related procedures&#xD;
             being performed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity or previous allergic reaction to any constituent of the&#xD;
             Investigational Products (i.e., essential oils, fragrance, choline,&#xD;
             phosphatidylcholine, etc.).&#xD;
&#xD;
          2. Any transient flushing syndrome.&#xD;
&#xD;
          3. History of basal cell carcinoma within 6 months of Visit 1.&#xD;
&#xD;
          4. History or presence of a skin condition/disease that is located in the treatment&#xD;
             area(s) and might interfere with the diagnosis or evaluation of study parameters&#xD;
             (i.e., atopic dermatitis, psoriasis, significant actinic damage, vitiligo, open&#xD;
             wounds, infection, etc.).&#xD;
&#xD;
          5. Diagnosis of severe rosacea, ocular rosacea, rhinophymatous rosacea, or acne fulminans&#xD;
             at Baseline.&#xD;
&#xD;
          6. Blepharitis/meibomianitis requiring systemic treatment by an ophthalmologist.&#xD;
&#xD;
          7. Uncontrolled systemic disease.&#xD;
&#xD;
          8. Foreseen unprotected and intense/excessive UV exposure during the course of the study.&#xD;
&#xD;
          9. Use of any of the following concomitant medications/procedures:&#xD;
&#xD;
               -  Cosmetic and/or OTC products for redness reduction and/or skin clearing&#xD;
&#xD;
               -  Topical medications for rosacea&#xD;
&#xD;
               -  Systemic antibiotics or corticosteroids&#xD;
&#xD;
               -  Topical antibiotics, corticosteroids, or antiparasitic agents&#xD;
&#xD;
               -  Intense/excessive ultraviolet (UV) radiation&#xD;
&#xD;
               -  Phototherapy, energy-based therapy, facials, chemical peels, microdermabrasion&#xD;
&#xD;
         10. Exposure to any other investigational drug/device within 30 days prior to study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cage Bio Investigative Site 1</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cage Bio Investigative Site 2</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cage Bio Investigative Site 3</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <zip>32132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 7, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2020</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

